查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606318

細胞和基因治療藥物傳輸設備市場：依產品和非處方藥 - 2025-2030 年全球預測

Cell & Gene Therapy Drug Delivery Devices Market by Products (Extension Tube, Infusion Bags, Intravenous Catheter), Commercialized Drugs (Kymriah, Luxturna, Provenge) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年細胞和基因治療給藥設備市場價值為10.8億美元，預計2024年將達到11.7億美元，複合年成長率為9.78%，2030年將達到20億美元，預計將達到80美元百萬。

細胞和基因治療藥物傳輸設備市場涵蓋將治療藥物輸送到特定細胞和基因以治療和糾正遺傳性疾病和其他重大疾病的創新技術。這些設備對於提高治療準確性和效率、最大限度地減少脫靶效應並最大限度地發揮治療潛力至關重要。應用範圍涵蓋腫瘤學、罕見遺傳疾病和免疫性疾病，主要最終用戶包括研究機構、醫院和生物製藥公司。細胞和基因療法的日益普及、輸送系統的技術進步以及基因研究資金和投資的增加推動了成長。將人工智慧整合到個人化治療方法、開發非病毒傳遞方法以及與科技和生物技術公司合作建立多功能傳遞平台方面將會出現機會。策略建議包括技術開發夥伴關係、新興市場投資以及專注於以患者為中心的交付解決方案。然而，這個市場面臨著高成本、嚴格的監管要求和複雜的製造流程等挑戰，這些挑戰可能會限制可擴展性和可近性。遺傳物料輸送固有的複雜性和專門的基礎設施需求進一步加劇了這些挑戰。創新成熟的領域包括開發新型奈米粒子、脂質載體和旨在提高安全性和有效性的生物分解性聚合物。此外，基於 CRISPR 的遞送系統的探索和微流體技術的進步為市場的發展帶來了巨大的希望。創新應解決最佳化交付機制、降低製造成本和提高交付準確性的問題。該市場的特點是技術快速發展和競爭激烈，鼓勵不斷的研究和合作。相關人員必須仔細掌握監管環境，同時促進滿足臨床需求和改善治療結果的創新。

主要市場統計
基準年[2023] 10.8億美元
預測年份 [2024] 11.7億美元
預測年份 [2030] 20.8億美元
複合年成長率（%） 9.78%

市場動態：快速發展的細胞和基因治療藥物輸送設備市場的關鍵市場洞察

細胞和基因治療藥物輸送設備市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病和遺傳疾病增加
    • 細胞和遺傳疾病藥物核准數量增加
    • 需要先進藥物傳輸系統的臨床試驗和治療的增加
  • 市場限制因素
    • 藥物輸送裝置高成本
  • 市場機會
    • 奈米技術和生物材料的發展進展
    • 在藥物傳輸中利用人工智慧、機器學習和感測器技術
  • 市場挑戰
    • 基因治療面臨複雜的監管挑戰以及獲得醫療設備核准的困難

波特五力：引領細胞與基因治療藥物傳遞設備市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對細胞和基因治療藥物輸送設備市場的影響

外部宏觀環境因素在塑造細胞和基因治療藥物傳輸設備市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解細胞/基因治療藥物輸送設備市場的競爭狀況

對細胞和基因治療藥物輸送設備市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣細胞和基因治療藥物傳輸設備市場供應商的績效評估

FPNV定位矩陣是評估細胞和基因治療藥物傳輸設備市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，描繪細胞和基因治療藥物傳輸設備市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對細胞和基因治療藥物輸送設備市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病和遺傳疾病增加
      • 更多針對細胞和遺傳疾病的藥物核准
      • 需要先進藥物傳輸系統的臨床試驗和治療的增加
    • 抑制因素
      • 藥物輸送裝置高成本
    • 機會
      • 奈米技術的進步和生物材料的開發
      • 在藥物傳輸中利用人工智慧、機器學習和感測器技術
    • 任務
      • 基因治療複雜的監管挑戰和醫療設備核准困難
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章細胞/基因治療藥物傳遞設備市場：依產品

  • 延長管
  • 點滴袋
  • 靜脈導管
  • 預填充式注射器
  • 無菌胰島素注射器
  • 視網膜下注射插管

第7章按已上市藥物分類的細胞/基因治療藥物傳輸設備市場

  • 基姆裡亞
  • 勒克斯圖納
  • Provenge
  • 斯特里姆韋利斯
  • 耶穌憲章
  • 佐爾根斯馬

第8章美洲細胞/基因治療藥物傳輸設備市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太細胞與基因治療給藥設備市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲/中東/非洲細胞/基因治療藥物傳輸設備市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • Bausch & Lomb Incorporated
  • Becton, Dickinson and Company
  • Bluebird bio, Inc.
  • Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • Dendreon Pharmaceuticals LLC.
  • Helixmith Co., Ltd.
  • Kite Pharma, Inc. by Gilead
  • Kolon TissueGene, Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Pfizer, Inc.
  • Renova Therapeutics
  • Spark Therapeutics, Inc.
  • uniQure NV
  • Vericel Corporation
Product Code: MRR-5C6F41F5AF95

The Cell & Gene Therapy Drug Delivery Devices Market was valued at USD 1.08 billion in 2023, expected to reach USD 1.17 billion in 2024, and is projected to grow at a CAGR of 9.78%, to USD 2.08 billion by 2030.

The scope of the market for cell and gene therapy drug delivery devices focuses on innovative technologies that facilitate the targeted delivery of therapeutic agents to specific cells or genes to treat or modify genetic disorders and other major diseases. These devices are essential for improving the precision and efficiency of therapies and minimizing off-target effects, thereby maximizing therapeutic potential. Applications extend across oncology, rare genetic disorders, and immunological conditions, with key end-users including research institutes, hospitals, and biopharmaceutical companies. Growth is driven by the escalating adoption of cell and gene therapies, technological advancements in delivery systems, and increased funding and investments in genetic research. Opportunities emerge in the integration of artificial intelligence for personalization of therapies, development of non-viral delivery methods, and the collaboration between technology firms and biotech companies to create multi-functional delivery platforms. Strategic recommendations include partnerships for technology development, investing in emerging markets, and focus on patient-centric delivery solutions. However, the market faces challenges such as high costs, stringent regulatory requirements, and complex manufacturing processes, which can limit scalability and accessibility. The inherent complexity of genetic material handling and the need for specialized infrastructure further exacerbate these challenges. Areas ripe for innovation include the development of novel nanoparticles, lipid-based carriers, and biodegradable polymers designed to improve safety and efficacy. Additionally, the exploration of CRISPR-based delivery systems and advancements in microfluidic technology offer significant promise for the market's evolution. Innovation should address the optimization of delivery mechanisms, reduction of manufacturing costs, and enhancement of delivery precision. The market is characterized by rapid technological evolution and high competition, encouraging continual research and collaboration. Stakeholders must navigate regulatory landscapes carefully while fostering innovation that aligns with clinical needs and enhances therapeutic outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 1.08 billion
Estimated Year [2024] USD 1.17 billion
Forecast Year [2030] USD 2.08 billion
CAGR (%) 9.78%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Drug Delivery Devices Market

The Cell & Gene Therapy Drug Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of chronic and genetic disorders
    • Growing number of drug approvals for treatment of cellular and genetic disorders
    • Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
  • Market Restraints
    • High cost of drug delivery devices
  • Market Opportunities
    • Advancements in nanotechnology and development of biomaterials
    • Utilization of AI, ML, and sensor technologies for drug delivery
  • Market Challenges
    • Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Drug Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Drug Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Drug Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Drug Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Drug Delivery Devices Market

A detailed market share analysis in the Cell & Gene Therapy Drug Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Drug Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Drug Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Drug Delivery Devices Market

A strategic analysis of the Cell & Gene Therapy Drug Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Drug Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC, Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd., Kite Pharma, Inc. by Gilead, Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics, Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Drug Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products, market is studied across Extension Tube, Infusion Bags, Intravenous Catheter, Pre-Filled Syringe, Sterile Insulin Syringe, and Subretinal Injection Cannula.
  • Based on Commercialized Drugs, market is studied across Kymriah, Luxturna, Provenge, Strimvelis, Yescarta, and Zolgensma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of chronic and genetic disorders
      • 5.1.1.2. Growing number of drug approvals for treatment of cellular and genetic disorders
      • 5.1.1.3. Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug delivery devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in nanotechnology and development of biomaterials
      • 5.1.3.2. Utilization of AI, ML, and sensor technologies for drug delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Drug Delivery Devices Market, by Products

  • 6.1. Introduction
  • 6.2. Extension Tube
  • 6.3. Infusion Bags
  • 6.4. Intravenous Catheter
  • 6.5. Pre-Filled Syringe
  • 6.6. Sterile Insulin Syringe
  • 6.7. Subretinal Injection Cannula

7. Cell & Gene Therapy Drug Delivery Devices Market, by Commercialized Drugs

  • 7.1. Introduction
  • 7.2. Kymriah
  • 7.3. Luxturna
  • 7.4. Provenge
  • 7.5. Strimvelis
  • 7.6. Yescarta
  • 7.7. Zolgensma

8. Americas Cell & Gene Therapy Drug Delivery Devices Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cell & Gene Therapy Drug Delivery Devices Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Bausch & Lomb Incorporated
  • 3. Becton, Dickinson and Company
  • 4. Bluebird bio, Inc.
  • 5. Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • 6. Dendreon Pharmaceuticals LLC.
  • 7. Helixmith Co., Ltd.
  • 8. Kite Pharma, Inc. by Gilead
  • 9. Kolon TissueGene, Inc.
  • 10. Novartis AG
  • 11. Orchard Therapeutics
  • 12. Pfizer, Inc.
  • 13. Renova Therapeutics
  • 14. Spark Therapeutics, Inc.
  • 15. uniQure N.V.
  • 16. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY EXTENSION TUBE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION BAGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS CATHETER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STERILE INSULIN SYRINGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBRETINAL INJECTION CANNULA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY KYMRIAH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY LUXTURNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PROVENGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STRIMVELIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY YESCARTA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ZOLGENSMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 108. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023